Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Deloitte
Harvard Business School
Novartis
Medtronic
Healthtrust
AstraZeneca
Accenture
Teva
Baxter

Generated: October 23, 2017

DrugPatentWatch Database Preview

BOEHRINGER INGELHEIM Company Profile

« Back to Dashboard

What is the competitive landscape for BOEHRINGER INGELHEIM, and what generic alternatives to BOEHRINGER INGELHEIM drugs are available?

BOEHRINGER INGELHEIM has forty-nine approved drugs.

There are one hundred and three US patents protecting BOEHRINGER INGELHEIM drugs and there have been four Paragraph IV challenges on BOEHRINGER INGELHEIM drugs in the past three years. There is one tentative approval on BOEHRINGER INGELHEIM drugs.

There are two thousand four hundred and seventy-eight patent family members on BOEHRINGER INGELHEIM drugs in sixty-eight countries and one hundred and seventy-eight supplementary protection certificates in fifteen countries.

Summary for Applicant: BOEHRINGER INGELHEIM

International Patents:2478
US Patents:103
Tradenames:40
Ingredients:30
NDAs:49
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim
OFEV
nintedanib esylate
CAPSULE;ORAL205832-001Oct 15, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Boehringer Ingelheim
TRADJENTA
linagliptin
TABLET;ORAL201280-001May 2, 2011RXYesYes► Subscribe► Subscribe ► Subscribe
Boehringer Ingelheim
STRIVERDI RESPIMAT
olodaterol hydrochloride
SPRAY, METERED;INHALATION203108-001Jul 31, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Boehringer Ingelheim
JENTADUETO
linagliptin; metformin hydrochloride
TABLET;ORAL201281-003Jan 30, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-3
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-003Oct 10, 1984ABRXYesYes► Subscribe► Subscribe► Subscribe
Boehringer Ingelheim
COMBIVENT RESPIMAT
albuterol sulfate; ipratropium bromide
SPRAY, METERED;INHALATION021747-001Oct 7, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
Boehringer Ingelheim
STRIVERDI RESPIMAT
olodaterol hydrochloride
SPRAY, METERED;INHALATION203108-001Jul 31, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Boehringer Ingelheim
JARDIANCE
empagliflozin
TABLET;ORAL204629-001Aug 1, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Boehringer Ingelheim
SPIRIVA RESPIMAT
tiotropium bromide
SPRAY, METERED;INHALATION021936-002Sep 15, 2015RXYesNo► Subscribe► SubscribeY► Subscribe
Boehringer Ingelheim
TRADJENTA
linagliptin
TABLET;ORAL201280-001May 2, 2011RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Boehringer Ingelheim

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim
JENTADUETO XR
linagliptin; metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL208026-002May 27, 2016► Subscribe► Subscribe
Boehringer Ingelheim
SPIRIVA RESPIMAT
tiotropium bromide
SPRAY, METERED;INHALATION021936-002Sep 15, 2015► Subscribe► Subscribe
Boehringer Ingelheim
ATROVENT HFA
ipratropium bromide
AEROSOL, METERED;INHALATION021527-001Nov 27, 2004► Subscribe► Subscribe
Boehringer Ingelheim
CATAPRES-TTS-3
clonidine
FILM, EXTENDED RELEASE;TRANSDERMAL018891-003Oct 10, 1984► Subscribe► Subscribe
Boehringer Ingelheim
MEXITIL
mexiletine hydrochloride
CAPSULE;ORAL018873-003Dec 30, 1985► Subscribe► Subscribe
Boehringer Ingelheim
JENTADUETO
linagliptin; metformin hydrochloride
TABLET;ORAL201281-003Jan 30, 2012► Subscribe► Subscribe
Boehringer Ingelheim
MIRAPEX
pramipexole dihydrochloride
TABLET;ORAL020667-002Jul 1, 1997► Subscribe► Subscribe
Boehringer Ingelheim
MIRAPEX
pramipexole dihydrochloride
TABLET;ORAL020667-005Jul 1, 1997► Subscribe► Subscribe
Boehringer Ingelheim
MICARDIS HCT
hydrochlorothiazide; telmisartan
TABLET;ORAL021162-003Apr 19, 2004► Subscribe► Subscribe
Boehringer Ingelheim
FLOMAX
tamsulosin hydrochloride
CAPSULE;ORAL020579-001Apr 15, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BOEHRINGER INGELHEIM drugs

Drugname Dosage Strength Tradename Submissiondate
afatinib dimaleate
Tablets 20 mg, 30 mg and 40 mg 
GILOTRIF
7/12/2017
dabigatran etexilate mesylate
Capsuleseq. to 110 mg base
PRADAXA
12/15/2015
linagliptin
Tablets5 mg
TRADJENTA
5/4/2015
linagliptin and metformin hydrochloride
Tablets2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg
JENTADUETO
5/4/2015
dabigatran etexilate mesylate
Capsuleseq. to 75 mg base and 150 mg base
PRADAXA
10/20/2014
nevirapine
Extended-release Tablets400 mg
VIRAMUNE XR
6/21/2013
pramipexole dihydrochloride
Extended-release Tablets2.25 mg and 3.75 mg
MIRAPEX ER
7/26/2011
pramipexole dihydrochloride
Extended-release Tablets0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg
MIRAPEX ER
6/1/2010
meloxicam
Oral Suspension7.5 mg/5 mL
MOBIC
12/17/2009
telmisartan and hydrochlorothiazide
Tablets80 mg/25 mg
MICARDIS HCT
2/27/2009
telmisartan and hydrochlorothiazide
Tablets80 mg/12.5 mg and 40 mg/12.5 mg
MICARDIS HCT
12/31/2008
pramipexole dihydrochloride
Tablets0.75 mg
MIRAPEX
7/31/2008
aspirin and dipyridamole
Extended-release Capsules25 mg and 200 mg
AGGRENOX
2/1/2007
telmisartan
Tablets20 mg, 40 mg and 80 mg
MICARDIS
12/26/2006
pramipexole dihydrochloride
Tablets0.125 mg, 0.5 mg, 1 mg and 1.5 mg
MIRAPEX
6/24/2005
pramipexole dihydrochloride
Tablets0.25 mg
MIRAPEX
5/27/2005
tamsulosin hydrochloride
Capsules0.4 mg
FLOMAX
12/20/2004

Non-Orange Book Patents for Boehringer Ingelheim

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,513,190Method of regulating glucose metabolism, and reagents related thereto► Subscribe
5,911,851 Atomizing nozzle and filter and spray generating device► Subscribe
8,486,398Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds► Subscribe
8,377,977Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof► Subscribe
5,610,163 Esters of thienyl carboxylic acids and amino alcohols and their quaternization products► Subscribe
7,157,429Method of regulating glucose metabolism, and reagents related thereto► Subscribe
6,169,181 Compounds useful to treat retroviral infections► Subscribe
6,503,440 Process for making a container with a pressure equalization opening and containers produced accordingly► Subscribe
9,089,571Quinazoline derivatives for the treatment of cancer diseases► Subscribe
7,820,815Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Boehringer Ingelheim Drugs

Country Document Number Estimated Expiration
Hong Kong1015715► Subscribe
Australia766219► Subscribe
Turkey9801234► Subscribe
Colombia6251239► Subscribe
Austria252564► Subscribe
South Korea20110107810► Subscribe
Slovenia1254678► Subscribe
Georgia, Republic ofP20156341► Subscribe
South Korea20120007088► Subscribe
Canada2897719► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Boehringer Ingelheim Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014 00065Denmark► SubscribePRODUCT NAME: LINAGLIPTIN; REG. NO/DATE: EU/1/11/707/001-011 20110830
00504Netherlands► SubscribePRODUCT NAME: LINAGLIPTINE, DESGEWENST IN DE VORM VAN ZOUT; REGISTRATION NO/DATE: EU/1/11/707/001-011 20110824
/1999Austria► SubscribePRODUCT NAME: TELMISARTAN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; NAT. REGISTRATION NO/DATE: EU/1/98/089/001-010 19981211; FIRST REGISTRATION: BE K (1998) 4288-DE 19981211
2015015Lithuania► SubscribePRODUCT NAME: NINTEDANIBUM; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141121
0725Netherlands► SubscribePRODUCT NAME: NINTEDANIB, DE TAUTOMEREN DAARVAN EN DE ZOUTEN DAARVAN, IN HET BIJZONDER NINTEDANIB EN FYSIOLOGISCH AANVAARDBARE ZOUTEN DAARVAN, MET NAME NINEDANIBESILAAT; REGISTRATION NO/DATE: EU/1/14/954/001-004 20141125
2014042Lithuania► SubscribePRODUCT NAME: VILDAGLIPTINUM; REGISTRATION NO/DATE: EU/1/07/414/001-010, 2007 09 26 EU/1/07/414/018 20070926
1730131/02Switzerland► SubscribePRODUCT NAME: EMPAGLIFLOZIN UND METFORMINHYDROCHLORID; REGISTRATION NO/DATE: SWISSMEDIC 65570 12.11.2015
C0039France► SubscribePRODUCT NAME: TIOTROPIUM MONOHYDRATE DE BROMURE; NAT. REGISTRATION NO/DATE: NL 31393 20050708; FIRST REGISTRATION: RVG 26191 20011009
90016-1Sweden► SubscribePRODUCT NAME: OLODATEROL, INDIVIDUELLA OPTISKA ISOMERER DAERAV, BLANDNINGAR AV DE SEPARATA ENANTIOMERERNA ELLER RACEMATEN DAERAV, SYRA ADDITIONSSALTER DAERAV MED FARMAKOLOGISKT GODTAGBARA SYROR SAVAEL SOM SOLVATER OCH/ELLER HYDRATER DAERAV, SAERSKILT OLODATEROL OCH OLODATEROLHYDROKLORID; NAT. REG. NO/DATE: MT-NR 48116 20131114; FIRST REG.: MT MA 211/00401 20130918
370Luxembourg► SubscribePRODUCT NAME: AFATINIB,LES TAUTOMERES,LES STEREOISOMERES ET LES SELS DE CELUI-CI,DES SELS PHYSIOLOGIQUEMENT ACCEPTABLES DE CELUI-CI AVEC DES ACIDES OU BASES ORGANIQUES OU INORGANIQUES,DE PREFERENCE UN SEL MALEATE DE CELUI-CI,ET PLUS DE PREFERENCE UN SEL DIMALEATE DE CELUI-CI
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Moodys
Deloitte
Daiichi Sankyo
Mallinckrodt
Covington
Queensland Health
Harvard Business School
Chubb
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot